Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Covenant Health, US
30 participants
Jun 10, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Eligibility
Inclusion Criteria3
- Ages 60 to 90 years old
- No prior diagnosis of dementia
- Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state
Exclusion Criteria2
- Age under 60 years
- Prior diagnosis of dementing illness or other organic etiology to cognitive impairment
Interventions
Blood will be collected and sent for testing using the Quest AD-Detect blood test
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07222280